Compare Johnson & Johnson (JNJ) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Upwork Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: Johnson & Johnson is far larger — about 577.7× Upwork Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Upwork Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Upwork Inc for 38 Days on average.
| JNJ | UPWK | |
|---|---|---|
Market Cap | $618.09B | $1.07B |
Volume | 6,050,983 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $278.43 | $22.11 |
52-Week Low | $186.00 | $7.84 |
Typical Hold Time | 129 Days | 38 Days |
Enterprise Value | $646.37B | $833.01M |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Upwork (UPWK) trades at $8.60, up 2.38% today, with a bearish technical signal despite recent earnings beat. The stock shows strong fundamentals with 77.21% gross margins and 12.93% net income margin, though revenue growth has stalled at $788M in 2025. Recent insider selling and ongoing securities fraud investigations create headwinds, while institutional buying from Bank of America provides some support. Technical indicators show resistance at $9 and support at $8.
The stock presents a mixed outlook with attractive valuation metrics (P/E 10.99, P/S 1.48) but faces significant AI disruption risks and declining active clients. Analyst consensus leans bullish with $9.64 price target, though near-term challenges from weak guidance and legal scrutiny may limit upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
